Seven plus eight makes six for Globus
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
The slow death of the medtech Spac deal
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
Novocure aims to plough a new field
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
